what manufacturer markets benicar
Benicar, or olmesartan medoxomil, is produced and marketed by Daiichi Sankyo, which gained FDA approval for the drug in 2002. Since its release on the U.S. market, Benicar prescriptions have skyrocketed, with some 10 million patients taking the medication in 2012. It is the only known angiotensin II receptor blocker â or ARB â that has been associated with serious and sometimes life-threatening gastrointestinal health issues.